TEPEZZA Dosing Information

The importance of completing full treatment course

8 IV Infusions

1 given every 3 weeks1

  • Infusion 1: 10 mg/kg – 90 min1
  • Infusion 2: 20 mg/kg – 90 min 
  • Infusions 3-8: 20 mg/kg – 60 min*
  • TEPEZZA dosing is based on the patient’s actual weight

*If not well tolerated, the minimum infusion duration should remain at 90 minutes.

Find your patient’s dose

The below charts are intended to provide dosing calculations for each infusion stage for patients ranging from 40 kg to 182 kg. The dosing values can also be downloaded as a PDF.

Dosing Calculations

Determine the dosing and infusion values for your patient1

Patients weighing 88 lbs to 168 lbs / 40 kg to 76 kg
Patient WeightInfusion 1 (10 mg/kg)Infusions 2 to 8 (20 mg/kg)
lb*kg*Dose (mg)Vials
required (#)
Volume to
withdraw (mL)
Dose (mg)Vials
required (#)
Volume to
withdraw (mL)
884040018.0800216.8
904141018.6820217.2
934242018.8840217.6
954343019.0860218.1
974444019.2880218.5
994545019.5900218.9
1014646019.7920219.3
1044747019.9940219.7
10648480110.1960220.2
10849490110.4980220.6
11050500110.61000221.0
11251510210.71020321.4
11552520210.91040321.8
11753530211.11060322.3
11954540211.31080322.7
12155550211.61100323.1
12356560211.81120323.5
12657570212.01140323.9
12858580212.21160324.4
13059590212.41180324.8
13260600212.61200325.2
13561610212.91220325.6
13762620213.11240326.1
13963630213.21260326.5
14164640213.41280326.9
14365650213.71300327.3
14666660213.91320327.7
14867670214.11340328.1
15068680214.31360328.6
15269690214.51380329.0
15470700214.71400329.4
15771710214.91420329.8
15972720215.21440330.2
16173730215.31460330.7
16374740215.51480331.1
16575750215.71500331.5
16876760215.91520331.9
Patients weighing 170 lbs to 247 lbs / 77 kg to 112 kg
Patient WeightInfusion 1 (10 mg/kg)Infusions 2 to 8 (20 mg/kg)
lb*kg*Dose (mg)Vials required(#)Volume to withdraw (mL)Dose (mg)Vials required(#)Volume to withdraw (mL)
17077770216.21540432.4
17278780216.41560432.8
17479790216.61580433.2
17680800216.81600433.6
17981810217.01620434.0
18182820217.21640434.5
18383830217.41660434.9
18584840217.61680435.3
18785850217.91700435.7
19086860218.11720436.1
19287870218.31740436.6
19488880218.51760437.0
19689890218.71780437.4
19890900218.91800437.8
20191910219.11820438.2
20392920219.31840438.7
20593930219.51860439.1
20794940219.71880439.5
20995950220.01900439.9
21296960220.21920440.3
21497970220.41940440.8
21698980220.61960441.2
21899990220.81980441.6
2211001000221.02000442.0
2231011010321.22020542.4
2251021020321.42040542.9
2271031030321.62060543.3
2291041040321.82080543.7
2321051050322.12100544.1
2341061060322.32120544.5
2361071070322.52140545.0
2381081080322.72160545.4
2401091090322.92180545.8
2431101100323.12200546.2
2451111110323.32220546.6
2471121120323.52240547.1
Patients weighing 249 lbs to 326 lbs / 113 kg to 148 kg
Patient WeightInfusion 1 (10 mg/kg)Infusions 2 to 8 (20 mg/kg)
lb*kg*Dose (mg)Vials required (#)Volume to withdraw (mL)Dose (mg)Vials required (#)Volume to withdraw (mL)
2491131130323.72260547.5
2511141140323.92280547.9
2541151150324.22300548.3
2561161160324.42320548.7
2581171170324.62340549.2
2601181180324.82360549.6
2621191190325.02380550.0
2651201200325.22400550.4
2671211210325.42420550.8
2691221220325.62440551.3
2711231230325.82460551.7
2731241240326.12480552.1
2761251250326.32500552.5
2781261260326.52520652.9
2801271270326.72540653.4
2821281280326.92560653.8
2841291290327.12580654.2
2871301300327.32600654.6
2891311310327.52620655.0
2911321320327.72640655.5
2931331330327.92660655.9
2951341340328.22680656.3
2981351350328.42700656.7
3001361360328.62720657.1
3021371370328.82740657.6
3041381380329.02760658.0
3061391390329.22780658.4
3091401400329.42800658.8
3111411410329.62820659.2
3131421420329.82840659.7
3151431430330.02860660.1
3181441440330.32880660.5
3201451450330.52900660.9
3221461460330.72920661.3
3241471470330.92940661.8
3261481480331.12960662.2
Patients weighing 329 lbs to 401 lbs / 149 kg to 182 kg
Patient WeightInfusion 1 (1.0 mg/kg)Infusions 2 to 8 (20 mg/kg)
lb*kg*Dose (mg)Vials required(#)Volume to withdraw (mL)Dose (mg)Vials required(#)Volume to withdraw (mL)
3291451490331.12960662.6
3311501500331.53000663.0
3331511510431.73020763.4
3351521520431.93040763.9
3371531530432.13060764.3
3401541540432.43080764.7
3421551550432.63100765.1
3441561560432.83120765.5
3461571570433.03140766.0
3481581580433.23160766.4
3511591590433.43180766.8
3531601600433.63200767.2
3551611610433.83220767.6
3571621620434.03240768.1
3591631630434.23260768.5
3621641640434.53280768.9
3641651650434.73300769.3
3661661660434.93320769.7
3681671670435.13340770.2
3701681680435.33360770.6
3731691690435.53380771.0
3751701700435.73400771.4
3771711710435.93420771.8
3791721720436.13440772.3
3811731730436.33460772.7
3841741740436.63480773.1
3861751750436.83500773.5
3881761760437.03520873.9
3901771770437.23540874.4
3921781780437.43560874.8
3951791790437.63580875.2
3971801800437.83600875.6
3991811810438.03620876.1
4011821820438.23640876.5

*Rounded to the nearest whole number.

Rounded to the nearest tenth.

Saline-bag

Saline bag size:

  • If dose is <1800 mg, use a 100-mL bag of normal saline (0.9% NaCl)1

  • If dose is ≥1800 mg, use a 250-mL bag of normal saline (0.9% NaCl)1

IV, intravenous.

In a post hoc analysis, 63% (n=15/24) of TEPEZZA patients who showed no proptosis improvement midway (12 weeks) through treatment ultimately did have a proptosis response after completing 8 infusions at 24 weeks from baseline.2
Randi

"After the second infusion, my symptoms seemed to decrease, and that motivated me to continue."

—Randi C., real TEPEZZA patient

In the Phase 3 study, improvement of proptosis as measured by mean change from baseline was observed as early as 6 weeks and continued to improve through Week 24.1

Nearly
OUT
OF

patients with TED would prefer IV medicine before trying eye surgery4

Based on a survey of 102 TED patients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Full Prescribing Information for more information.

REFERENCES:

1. TEPEZZA (teprotumumab-trbw) [prescribing information] Amgen. 2. Ugradar S, Wang Y, Mester T, et al. Teprotumumab for thyroid eye disease: early response is not required for benefit. Eye (Lond). 2022;36(7):1403-1408. 3. Supplement to: Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352. 4. Data on File. Amgen, January 2023.